

# Endurance training improves oxygen uptake/demand mismatch, metabolic flexibility and recovery in patients with sickle cell disease

Loïs Mougin,<sup>1\*</sup> Manon Riccetti,<sup>1\*</sup> Angèle N. Merlet,<sup>2,3</sup> Pablo Bartolucci,<sup>4,5</sup> Barnabas Gellen,<sup>6</sup> Léo Blervaque,<sup>1</sup> Thomas d'Humières,<sup>5,7,8</sup> Frédéric Galactéros,<sup>4,5</sup> Chi-An W. Emhoff,<sup>1,9</sup> Léonard Féasson<sup>2,3</sup> and Laurent A. Messonnier<sup>1,10</sup>

<sup>1</sup>Inter-university Laboratory of Human Movement Sciences, University Savoie Mont Blanc, Chambéry, France; <sup>2</sup>Inter-university Laboratory of Human Movement Sciences, University Jean Monnet, Saint-Etienne, France; <sup>3</sup>Myology Unit, Department of Clinical Physiology and Exercise, Saint-Etienne University Hospital, Saint-Etienne, France; <sup>4</sup>Department of Internal Medicine, Henri-Mondor Hospital (AP-HP), University Paris-Est Créteil (UPEC), Créteil, France; <sup>5</sup>Sickle Cell Referral Center - UMGGR, Great Paris East Rare Diseases Expertise Platform, UPEC, FHU SENEK, Henri-Mondor Hospital (AP-HP), Créteil, France; <sup>6</sup>Department of Cardiac Rehabilitation, Henri-Mondor Hospital (AP-HP), Créteil, France; <sup>7</sup>Department of Physiology, FHU SENEK, Henri-Mondor Hospital (AP-HP), Créteil, France; <sup>8</sup>INSERM IMRB U955, Team 8, University Paris Est (UPEC), Créteil, France; <sup>9</sup>Department of Kinesiology, Saint Mary's College of California, Moraga, CA, USA and <sup>10</sup>Institut Universitaire de France (IUF), Paris, France

*\*LM and MR contributed equally as first authors.*

**Correspondence:** L.A. Messonnier  
[laurent.messonnier@univ-smb.fr](mailto:laurent.messonnier@univ-smb.fr)

**Received:** October 19, 2023.  
**Accepted:** March 26, 2024.  
**Early view:** April 4, 2024.

<https://doi.org/10.3324/haematol.2023.284474>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



## *Supplemental*

### **Endurance training improves oxygen uptake/demand mismatch, metabolic flexibility and recovery in patients with sickle cell disease**

Mougin *et al.*

#### **Supplemental information on the population of patients**

None of the patients displayed severe complications including chronic inflammatory or infectious disease, kidney insufficiency, clinical signs and/or history of heart failure, left ventricular ejection fraction <50%, pulmonary arterial hypertension with tricuspid regurgitation velocity >2.8 m/s, atrial fibrillation, ventricular arrhythmias, left ventricular hypertrophy, significant valvulopathy, known coronary disease, uncontrolled hypertension, treatment with anti-arrhythmia drugs (including  $\beta$ -blockers), current anti-coagulant treatment, a pacemaker or defibrillator, known cerebral vasculopathy, prior stroke and epilepsy.

#### **Supplemental results and discussion**

The slope coefficient of the  $\dot{V}O_2$  vs. W relationship has been reported to be lower in young adult and adult patients with SCD than in control subjects<sup>1-3</sup>. This lower slope coefficient likely results from lower muscle oxygen supply (due to anaemia, microvasculature rarefaction and low capillary/fibre surface of exchange) and/or lower muscle ability to consume oxygen (as testified by

lower oxidative enzymes activity, lower peripheral extraction and arterialisation of venous blood) in SCD patients<sup>4-6</sup>. These results and inferences are in total accordance with a previous study performed in patients with COVID-19 for whom the observed lower slope coefficient of the  $\dot{V}O_2$  vs. W relationship was concomitant to both lower arterial oxygen content and peripheral extraction during rest as well as exercise<sup>7</sup>.

In the present study, we recorded elevated RER values during rest and low-intensity exercise. Firstly, as mentioned in the main text, this is not the first time that elevated RER values are reported in SCD patients<sup>1,8-10</sup>. Second, these values cannot be related to metabolic cart dysfunction. Indeed, to ensure validity of gas exchange measurements, the metabolic cart underwent standard service before the study and at mid experiments. Furthermore, the metabolic cart underwent successful calibration before each measurement session. Additionally, the experiments took place over 18 months, during which time values remained similar. Furthermore, it cannot be argued that data are related to unsteady states. Supplemental figure 1 shows clearly that a steady state in oxygen uptake is reached during the last 10 breathing cycles of each stage of the submaximal incremental tests (SIT1 and SIT2). This is actually not surprising. Indeed, the increment between two successive stages is so small (10 W for women and 15 W for men) that even if the stage duration is rather short (2 min), a steady state is reached. Along the same line of reasoning, the steady state being obtained before and after training it cannot be argued that the improvement of the slope coefficient is false/fake and related to an unsteady state before training and a steady state after training. In the aggregate, the proper functioning of the metabolic cart and the steady states obtained during the last 20 seconds of each stage during SIT1 and SIT2 argue in favor of the facts that i) the RER values were correct, strongly suggesting acid/base disturbances in patients with SCD, ii) the change of the slope coefficient was real and not due to unsteady states before training and steady states

after training, and iii) when possible/appropriate, substrate partitioning calculation were reliable, strongly suggesting a predominantly carbohydrate utilization in patients with SCD.

The supplemental table 1 reports metabolic equivalent of task (MET) values for each patient during SIT1 as SIT2.

## References

1. Liem RI, Nevin MA, Prestridge A, Young LT, Thompson AA. Functional capacity in children and young adults with sickle cell disease undergoing evaluation for cardiopulmonary disease. *Am J Hematol.* 2009;84(10):645–9.
2. Messonnier LA, Gellen B, Lacroix R, et al. Physiological Evaluation for Endurance Exercise Prescription in Sickle Cell Disease. *Med Sci Sports Exerc.* 2019;51(9):1795–801.
3. Miller DM, Winslow RM, Klein HG, Wilson KC, Brown FL, Statham NJ. Improved Exercise Performance After Exchange Transfusion in Subjects With Sickle Cell Anemia. *Blood.* 1980;56(6):1127–31.
4. Detterich JA, Kato R, Bush A, et al. Sickle cell microvascular paradox-oxygen supply-demand mismatch. *Am J Hematol.* 2019;94(6):678–88.
5. Hammoudi N, Ceccaldi A, Haymann JP, et al. Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. *Eur J Clin Invest.* 2022;52(1):13664.
6. Ravelojaona M, Féasson L, Oyono-Enguélé S, et al. Evidence for a profound remodeling of skeletal muscle and its microvasculature in sickle cell anemia. *Am J Pathol.* 2015;185(5):1448–56.
7. Baratto C, Caravita S, Faini A, et al. Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. *J Appl Physiol (1985).* 2021;130(5):1470–8.
8. Alsaied T, Niss O, Powell AW, et al. Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia. *Pediatr Blood Cancer.* 2018;65(8):e27113.
9. Liem RI, Akinosun M, Muntz DS, Thompson AA. Feasibility and safety of home exercise training in children with sickle cell anemia. *Pediatr Blood Cancer.* 2017;64(12):e26671.
10. Liem RI, Reddy M, Pelligra SA, et al. Reduced fitness and abnormal cardiopulmonary responses to maximal exercise testing in children and young adults with sickle cell anemia. *Physiol Rep.* 2015; 3:e12338.

**Supplemental table 1:** Metabolic equivalent of task (MET) for each step of SIT1 and SIT2.


Males		30 W	45 W	60 W	75 W	90 W	105 W	120 W	135 W
1	SIT1	2.09	2.58	3.54	4.19	4.51			
	SIT2	2.74	3.18	3.74	4.19	4.95			
2	SIT1	2.36	4.02	3.95	4.32	4.75	5.95		
	SIT2	2.56	3.06	3.09	4.29	4.75	5.91		
3	SIT1	2.17	2.42	3.00					
	SIT2	1.63	2.24	2.71	<i>3.58</i>				
4	SIT1	1.72	2.77	3.24	3.95	4.45	<i>4.62</i>		
	SIT2	3.95	4.37	4.79	5.55	6.64	<i>6.60</i>		
5	SIT1	3.04	3.66	3.84	4.82	6.12			
	SIT2	2.72	3.53	3.93	5.00	<i>4.46</i>			
6	SIT1	2.65	3.35	4.04	4.24	<i>4.37</i>			
	SIT2	3.27	3.96	4.65	6.16	6.16			
7	SIT1	1.82	2.86	2.94	<i>3.55</i>				
	SIT2	2.99	3.72	4.55	5.54	5.54			
8	SIT1	2.37	3.35	3.67	4.04				
	SIT2	2.78	3.43	3.63	4.29	4.24	4.82	5.10	
Females		20 W	30 W	40 W	50 W	60 W	70 W	80 W	90 W
1	SIT1	1.78	2.20	2.34	2.95	3.19	3.23		
	SIT2	1.78	1.87	2.34	2.62	3.09	3.89	4.26	
2	SIT1	2.91	3.29	3.45	3.61	3.83	4.37	<i>4.91</i>	
	SIT2	2.16	2.53	3.29	3.56	4.26	4.64	5.07	5.23
3	SIT1	2.39	2.75	3.64	3.90	<i>4.42</i>			
	SIT2	2.55	2.86	3.27	4.00	<i>4.52</i>			
4	SIT1	2.55	2.62	2.86	2.62	3.10	3.34		
	SIT2	2.10	2.58	2.79	3.10	3.34	4.34	<i>4.72</i>	
5	SIT1	1.92	2.36	2.47	2.69				
	SIT2	2.42	2.58	2.75	3.35	<i>3.79</i>			
6	SIT1	3.38	3.44	3.91	4.49	5.42			
	SIT2	3.38	3.73	4.20	4.78	5.36			
7	SIT1	3.03	3.31	3.42	4.15				
	SIT2	2.91	3.31	3.75	4.31	4.59			

Values on the left hand side, in italic and grey were obtained at minute one of the two-minute stage.

## Figure legends

**Supplemental figure 1.** Typical  $\dot{V}O_2$  responses during the last 10 breathing cycles of each stage of SIT1 (before training, left panel) and SIT2 (after training, left panel) in four typical subjects (two males and two females).  $\dot{V}O_2$  is a wavelet mean value over 5 seconds. SIT: submaximal incremental exercise test.

# SIT1



# SIT2

